Iambic Therapeutics

Executive Summary

Iambic Therapeutics is a private AI-driven biotechnology company headquartered in San Diego, founded in 2019. The company has developed an integrated AI and automation platform that designs and optimizes novel small molecule therapeutics, aiming to accelerate the discovery of first-in-class and best-in-class medicines. Its internal pipeline is focused on oncology, with lead programs targeting HER2, KIF18A, and CDK2/4, all in early clinical or preclinical stages. By leveraging its proprietary platform, Iambic aims to reduce the time and cost of drug development while improving the probability of success. The company's platform has attracted attention from investors and partners, positioning it as a notable player in the AI-enabled drug discovery space. Iambic is currently advancing multiple programs through Phase 1 clinical trials. The most advanced candidate, targeting HER2, is expected to yield initial clinical data within the next year, which could serve as a key value inflection point. The company also continues to expand its pipeline through internal discovery and potential partnerships. Given its strong AI platform, experienced team, and focus on validated oncology targets, Iambic is well-positioned to generate meaningful clinical proof-of-concept data. However, as a private company with early-stage assets, the risk profile remains elevated, and success hinges on favorable safety and efficacy readouts.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 clinical data readout for lead HER2 programme45% success
• Q3 2026Series C or crossover financing round65% success
• Q4 2026IND filing for next pipeline candidate (e.g., CDK2/4 or KIF18A)55% success